Biogen shakes up R&D chief role, makes Singhal permanent replacement. By Allison DeAngelis Jan. 5, 2023. Reprints. Ruby Wallau for STAT. M ore than a year after Al Sandrock was pushed out as ...

Biogen expects to do better this year on a key metric of financial health after a strong performance this summer from its newer products, including Leqembi, the closely watched drug for Alzheimer ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Biogen now expects full-year adjusted earnings to come in at $15.75 to $16.25 per share, up from a previous forecast of $15 to $16 per share. The biotech company also expects 2024 sales to decline ...

Biogen Inc (NASDAQ: BIIB) reported its first quarter 2025 financial results on May 1, 2025, showing a 6% year-over-year revenue increase to $2.4 billion, driven by strong performance from its ...

Biogen’s $11 billion gain in market capitalization implies roughly $6.5 billion of sales in five years, assuming revenue split between the two companies, discounted at a rate of 10%, and valued ...

Uptake of Biogen’s breakthrough Alzheimer’s drug, Leqembi, appears to be picking up, with roughly $40 million in sales for the quarter. Skip to content. Main Navigation. Search.